News | Cardio-oncology | September 28, 2016

Cardiac Risk a Factor When Considering Hormonal Therapy for Prostate Cancer

Decision analysis model study shows men with low-risk prostate cancer and history of heart attack may be harmed by adding hormone therapy to radiation therapy

prostate cancer, hormone therapy, cardiac risk factors, Yale Cancer Center study, ASTRO 2016

September 28, 2016 — In a recent study, a Yale Cancer Center team determined that men who received hormonal therapy for prostate cancer had a net harm if they had a prior history of a heart attack. The findings were presented at the American Society for Radiation Oncology (ASTRO) meeting, Sept. 25-28 in Boston.

Hormone therapy is used for treatment of prostate cancer to block the production of androgens, or male sex hormones. Androgens are necessary for the growth and spread of prostate cancer cells. Hormone therapy suppresses the androgen production in the body and stops the spread and growth of prostate cancer cells.

This study used a previously published decision analysis model that compared quality-adjusted life years (QALYs) in men aged 50, 60 and 70 years who received radiation therapy and no hormone therapy for high-risk prostate cancer and their cardiac risk factors. The research team used data from the recently published EORTC 22991 trial to study men with intermediate-risk prostate cancer, randomized to either radiation therapy or radiation therapy and six months of hormone therapy.

Hormone therapy was associated with a net decrease of 0.3 – 0.4 QALYs in men with a prior history of heart attack. However, for all other men, hormone therapy improved QALYs (range 0.4 - 2.6). Younger men with fewer cardiac risk factors experienced the largest benefit from hormone therapy. Men at low risk for biochemical failure (≤8.7 percent at 5 years) did not benefit from hormone therapy. Further, the benefits of hormone therapy did not begin to manifest until after 7.3 years of follow-up.

“Patient age, cardiac risk, and disease recurrence risk should be considered when selecting candidates for hormone therapy in this patient population,” said Nataniel Lester-Coll, M.D., first author on the study and a resident in the Department of Therapeutic Radiology at Yale School of Medicine. “Men with a history of heart attack who are at very low risk for biochemical failure may be harmed by the addition of hormone therapy.”

For more information: www.astro.org

Related Content

High-dose Radiation Effective for Men Whose Prostate Cancer Has Spread
News | Prostate Cancer | September 23, 2019
A randomized clinical trial of targeted, high-dose radiation for men with oligometastatic prostate cancer has shown the...
First Patients Treated With Machine Learning-generated Plans from RayStation 8B
News | Treatment Planning | September 23, 2019
The first-ever patient radiation therapy treatments generated with machine learning in the RayStation treatment...
An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart. #ASTRO19 #ASTRO2019 #ASTRO

An example of a treatment plan for radio-ablation of the heart to noninvasively treat cardiac arrhythmias. This concept is one of the key presentations at the 2019 ASTRO meeting. Image courtesy of Cyberheart.

Feature | ASTRO | September 23, 2019
August 29, 2019 — The American Society for Radiation Oncology (ASTRO) announced th
Videos | Radiation Oncology | September 20, 2019
Anne Hubbard, MBA, director of health policy for ASTRO, explains the details and purpose of the proposed Radiation On
Videos | Radiation Therapy | September 20, 2019
ITN Associate Editor Jeff Zagoudis speaks with...
Aktina Showcases New Radiotherapy Patient Immobilization Solutions at ASTRO 2019
News | Patient Positioning Radiation Therapy | September 20, 2019
Aktina Medical introduced several new products at the 2019 American Society for Radiation Oncology (ASTRO) annual...
Varian Announces Multi-room Configuration for ProBeam 360 Proton Therapy System
News | Proton Therapy | September 20, 2019
Varian announced its ProBeam 360° proton therapy system is now available in a multi-room configuration. The ProBeam 360...
Anne Hubbard, MBA, director of health policy for the American Society for Radiation Oncology

Anne Hubbard, MBA, director of health policy for the American Society for Radiation Oncology (ASTRO), explains the details of the proposed radiation oncology alternative payment model (APM), and issues ASTRO has raised with the model, at the 2019 ASTRO annual meeting in Chicago.

News | Radiation Oncology | September 18, 2019
During its annual meeting in September, the American Society for Radiation Oncology (ASTRO) issued a response to the...
Radiation After Immunotherapy Improves Progression-free Survival for Some Metastatic Lung Cancer Patients
News | Lung Cancer | September 18, 2019
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates...
IBA Gathers Experts on Flash Irradiation During ASTRO
News | Proton Therapy | September 17, 2019
IBA (Ion Beam Applications SA, held its third Victoria Consortium Meeting focusing on Flash irradiation at the 2019...